Atlanta Cancer Care - Atlanta

Atlanta, Georgia 30342

0 studies enrolling now · 6 studies all time

What they study most

Advanced Breast Cancer, Advanced Gastric Cancer, Breast Cancer, Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, Genes, BRCA 1, HER2 Low Breast Neoplasms, HER2 Positive Breast Cancer, HER2 Positive Breast Neoplasms, HER2-positive Breast Cancer, Locally Advanced or Metastatic Solid Tumors, Metastatic Breast Cancer

Studies at this site

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Running, not enrolling
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors — Stopped early
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors — Stopped early
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed